Skip to main content

February 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology

Multiple Myeloma, Oncology
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Leukemia, Oncology
Asciminib, First-in-Class STAMP Inhibitor, Superior to Bosutinib in Chronic-Phase CML
Phoebe Starr
Read More
Multiple Myeloma, Oncology, Bispecific Antibodies
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
Wayne Kuznar
Read More
Gastroenterology
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
Phoebe Starr
Read More
FDA Approvals
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations
Read More
FDA Approvals
FDA Approves Margenza for Treatment of Metastatic HER2-Positive Breast Cancer
Read More
FDA Approvals
Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer
Read More
Page 3 of 3
Results 21 - 27 of 27